Jacques Grill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9466515/publications.pdf

Version: 2024-02-01

191	12 556	28274	28297
	12,556 citations	h-index	g-index
papers	citations	II-IIIQex	g-mdex
195	195	195	11785
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
2	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
3	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
4	Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathologica, 2015, 130, 815-827.	7.7	482
5	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
6	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	28.4	469
7	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423
8	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	1.6	273
9	Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology. Journal of Clinical Oncology, 2001, 19, 1288-1296.	1.6	258
10	Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncology, The, 2005, 6, 573-580.	10.7	250
11	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
12	Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients. Brain, 2003, 126, 152-160.	7.6	242
13	Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. Journal of Neurosurgery: Pediatrics, 2007, 106, 3-12.	1.3	225
14	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
15	Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas. PLoS ONE, 2012, 7, e30313.	2.5	200
16	Variable selection for generalized canonical correlation analysis. Biostatistics, 2014, 15, 569-583.	1.5	168
17	Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy—Results of the First French Prospective Study for the French Society of Pediatric Oncology. Journal of Clinical Oncology, 2003, 21, 4572-4578.	1.6	167
18	Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Therapy, 2000, 7, 901-904.	4.6	145

#	Article	IF	CITATIONS
19	Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Child's Nervous System, 2015, 31, 1773-1780.	1.1	145
20	Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research, 2002, 62, 5736-42.	0.9	142
21	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell, 2018, 33, 829-842.e5.	16.8	140
22	Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits. Lancet Oncology, The, 2012, 13, e445-e459.	10.7	134
23	Craniopharyngioma: the pendulum of surgical management. Child's Nervous System, 2005, 21, 691-695.	1.1	129
24	Stereotactic biopsy of diffuse pontine lesions in children. Journal of Neurosurgery: Pediatrics, 2007, 107, 1-4.	1.3	126
25	Vemurafenib in pediatric patients with <scp><i>BRAFV</i></scp> <i>600E</i> mutated highâ€grade gliomas. Pediatric Blood and Cancer, 2014, 61, 1101-1103.	1.5	125
26	Injuries to inferior vermis and dentate nuclei predict poor neurological and neuropsychological outcome in children with malignant posterior fossa tumors. Cancer, 2009, 115, 1338-1347.	4.1	118
27	When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. European Journal of Pediatrics, 2000, 159, 692-696.	2.7	113
28	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clinical Cancer Research, 2012, 18, 2001-2011.	7.0	111
29	Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatric Blood and Cancer, 2012, 58, 489-491.	1.5	111
30	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathologica, 2020, 139, 1109-1113.	7.7	104
31	Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Research, 2002, 62, 6165-71.	0.9	104
32	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clinical Cancer Research, 2017, 23, 6101-6112.	7.0	102
33	Patterns of neuropsychological deficits in children with medulloblastoma according to craniospatial irradiation doses. Developmental Medicine and Child Neurology, 2000, 42, 741-745.	2.1	102
34	Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system. Cancer, 2012, 118, 3812-3821.	4.1	101
35	Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2012, 106, 399-407.	2.9	100
36	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Journal of Clinical Oncology, 2018, 36, 951-958.	1.6	95

#	Article	IF	Citations
37	Diffuse intrinsic pontine gliomasâ€"current management and new biologic insights. Is there a glimmer of hope?. Neuro-Oncology, 2017, 19, 1025-1034.	1.2	91
38	Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Research, 2002, 62, 764-72.	0.9	89
39	Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished. Journal of Virology, 2002, 76, 2753-2762.	3.4	88
40	Transcriptomic and epigenetic profiling of  diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta Neuropathologica Communications, 2018, 6, 117.	5.2	83
41	Arterial Spin Labeling to Predict Brain Tumor Grading in Children: Correlations between Histopathologic Vascular Density and Perfusion MR Imaging. Radiology, 2016, 281, 553-566.	7.3	82
42	Coâ€occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathology, 2018, 28, 103-111.	4.1	80
43	Online Quality Control, Hyperfractionated Radiotherapy Alone and Reduced Boost Volume for Standard Risk Medulloblastoma: Long-Term Results of MSFOP 98. Journal of Clinical Oncology, 2009, 27, 1879-1883.	1.6	79
44	Thalamic tumors in children: a reappraisal. Journal of Neurosurgery: Pediatrics, 2007, 106, 354-362.	1.3	75
45	Childhood supratentorial ependymomas with <i>YAP1â€MAMLD1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	4.1	75
46	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . Neuro-Oncology, 2021, 23, 34-43.	1.2	75
47	The Therapy of Infantile Malignant Brain Tumors: Current Status?. Journal of Neuro-Oncology, 2005, 75, 279-285.	2.9	69
48	Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. Journal of Neurosurgery: Pediatrics, 2004, 101, 152-158.	1.3	67
49	Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genetics and Cytogenetics, 2006, 166, 74-81.	1.0	67
50	TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). Clinical Cancer Research, 2019, 25, 6788-6800.	7.0	66
51	Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Adî"24-p53 against Human Malignant Glioma. Cancer Research, 2004, 64, 5753-5759.	0.9	64
52	Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality. Brain, 2011, 134, 1362-1372.	7.6	60
53	Metastatic ependymoma: A multiâ€institutional retrospective analysis of prognostic factors. Pediatric Blood and Cancer, 2008, 50, 231-235.	1.5	59
54	High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer, 2007, 110, 156-163.	4.1	58

#	Article	IF	CITATIONS
55	Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genetics and Cytogenetics, 2002, 136, 121-125.	1.0	57
56	Clinical Relevance of Tumor Cells with Stem-Like Properties in Pediatric Brain Tumors. PLoS ONE, 2011, 6, e16375.	2.5	57
57	EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. International Journal of Cancer, 2008, 123, 209-216.	5.1	56
58	Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro-Oncology, 2015, 17, 953-964.	1,2	56
59	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
60	Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro-Oncology, 2010, 12, 1126-1134.	1,2	54
61	Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma. Journal of Neuropathology and Experimental Neurology, 2016, 75, 971-980.	1.7	54
62	Medulloblastoma in young children. Pediatric Blood and Cancer, 2010, 54, 635-637.	1.5	52
63	Germline <i>SUFU</i> mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro-Oncology, 2018, 20, 1122-1132.	1.2	52
64	Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. Journal of Medical Genetics, 2010, 47, 142-144.	3.2	51
65	Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Annals of Clinical and Translational Neurology, 2015, 2, 439-443.	3.7	51
66	High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. Neuro-Oncology, 2020, 22, 1190-1202.	1.2	50
67	Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatric Blood and Cancer, 2005, 45, 814-819.	1.5	49
68	Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. Journal of Neuro-Oncology, 2011, 104, 773-777.	2.9	48
69	Tandem highâ€dose chemotherapy and autologous stem cell rescue in children with newly diagnosed highâ€risk medulloblastoma or supratentorial primitive neuroâ€ectodermic tumors. Pediatric Blood and Cancer, 2014, 61, 1398-1402.	1.5	46
70	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 294-307.	7.4	45
71	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
72	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41

#	Article	IF	CITATIONS
73	New <i>in vivo</i> avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget, 2017, 8, 52543-52559.	1.8	41
74	Astrocytes Reverted to a Neural Progenitor-like State with Transforming Growth Factor Alpha Are Sensitized to Cancerous Transformation. Stem Cells, 2009, 27, 2373-2382.	3.2	39
75	Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study. European Journal of Pediatrics, 2012, 171, 25-32.	2.7	39
76	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology, 2015, 17, 1486-1496.	1.2	39
77	High-dose chemotherapy in childhood brain tumours. Child's Nervous System, 1999, 15, 498-505.	1.1	38
78	Childhood Ependymoma. Paediatric Drugs, 2003, 5, 533-543.	3.1	38
79	Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy. PLoS ONE, 2015, 10, e0127676.	2.5	38
80	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. British Journal of Clinical Pharmacology, 2016, 81, 148-160.	2.4	38
81	Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors. Cancer Letters, 2020, 479, 13-22.	7.2	38
82	The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Molecular Therapy, 2002, 6, 609-14.	8.2	37
83	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
84	Portrait of Ependymoma Recurrence in Children: Biomarkers of Tumor Progression Identified by Dual-Color Microarray-Based Gene Expression Analysis. PLoS ONE, 2010, 5, e12932.	2.5	35
85	Cerebellar mutism: definitions, classification and grading of symptoms. Child's Nervous System, 2011, 27, 1361-1363.	1.1	35
86	Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. SpringerPlus, 2016, 5, 879.	1.2	35
87	Long Time to Diagnosis of Medulloblastoma in Children Is Not Associated with Decreased Survival or with Worse Neurological Outcome. PLoS ONE, 2012, 7, e33415.	2.5	34
88	Low Bone Mineral Density and High Incidences of Fractures and Vitamin D Deficiency in 52 Pediatric Cancer Survivors. Hormone Research in Paediatrics, 2010, 74, 319-327.	1.8	33
89	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 383-386.	1.5	33
90	Cognitive and Academic Outcome After Benign or Malignant Cerebellar Tumor in Children. Cognitive and Behavioral Neurology, 2009, 22, 270-278.	0.9	32

#	Article	IF	Citations
91	A common polymorphism in the $5\hat{a}\in^2$ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. Genes and Development, 2015, 29, 1891-1896.	5 . 9	32
92	Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy. Journal of Pediatric Hematology/Oncology, 2015, 37, e102-e110.	0.6	31
93	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. American Journal of Neuroradiology, 2016, 37, 1581-1587.	2.4	31
94	Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors. Neuron, 2020, 108, 1025-1044.	8.1	31
95	Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives. Neurosurgical Focus, 2020, 48, E10.	2.3	31
96	p53 pathway dysfunction in primary childhood ependymomas. Pediatric Blood and Cancer, 2006, 46, 604-613.	1.5	30
97	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2019, 141, 253-263.	2.9	30
98	Pediatric infratentorial gangliogliomas: a retrospective series. Journal of Neurosurgery: Pediatrics, 2007, 107, 286-291.	1.3	27
99	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
100	NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro-Oncology, 2021, 23, 100-111.	1.2	27
101	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neuro-Oncology Advances, 2021, 3, vdab013.	0.7	27
102	Central nervous system germ cell tumors. Current Opinion in Oncology, 2014, 26, 622-626.	2.4	26
103	Inhibition of the NOTCH pathway using \hat{I}^3 -secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Anti-Cancer Drugs, 2015, 26, 272-283.	1.4	26
104	Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. Journal of Neuroradiology, 2018, 45, 316-322.	1.1	26
105	WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro-Oncology, 2020, 22, 116-127.	1.2	26
106	Measuring the neuro-cognitive side-effects of irradiation in children with brain tumors. Pediatric Blood and Cancer, 2004, 42, 452-456.	1.5	25
107	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	1.2	25
108	Repurposing Vandetanib plus Everolimus for the Treatment of <i> ACVR1 </i> > -Mutant Diffuse Intrinsic Pontine Glioma. Cancer Discovery, 2022, 12, 416-431.	9.4	25

#	Article	IF	Citations
109	Constitutional mismatch repair deficiency–associated brain tumors: report from the European C4CMMRD consortium. Neuro-Oncology Advances, 2019, 1, vdz033.	0.7	23
110	High-dose chemotherapy in children with newly-diagnosed medulloblastoma. Lancet Oncology, The, 2006, 7, 787-789.	10.7	22
111	Teachers' report of learning and behavioural difficulties in children treated for cerebellar tumours. Brain Injury, 2012, 26, 1014-1020.	1.2	21
112	Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas. Neuro-Oncology, 2018, 20, 994-1002.	1.2	21
113	Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathologica Communications, 2021, 9, 135.	5. 2	21
114	Recent development in chemotherapy of paediatric brain tumours. Current Opinion in Oncology, 2007, 19, 612-615.	2.4	20
115	Water and Electrolyte Disorders at Long-Term Post-Treatment Follow-Up in Paediatric Patients with Suprasellar Tumours Include Unexpected Persistent Cerebral Salt-Wasting Syndrome. Hormone Research in Paediatrics, 2014, 82, 364-371.	1.8	20
116	Relationships between Regional Radiation Doses and Cognitive Decline in Children Treated with Cranio-Spinal Irradiation for Posterior Fossa Tumors. Frontiers in Oncology, 2017, 7, 166.	2.8	20
117	The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population. Acta Neuropathologica, 2020, 139, 287-303.	7.7	19
118	In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts. Cancer Chemotherapy and Pharmacology, 2003, 51, 385-394.	2.3	18
119	Highâ€dose busulfan–thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 907-912.	1.5	18
120	The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of "CNS tumors with BCOR internal tandem duplication― Acta Neuropathologica Communications, 2020, 8, 178.	5.2	17
121	Relapses of optic pathway tumors after firstâ€line chemotherapy. Pediatric Blood and Cancer, 2009, 52, 575-580.	1.5	16
122	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. PLoS ONE, 2017, 12, e0178351.	2.5	15
123	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. Cancer Discovery, 2022, 12, 712-729.	9.4	15
124	Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival. Neuro-Oncology, 2012, 14, 1413-1421.	1.2	14
125	Disrupted sensorimotor synchronization, but intact rhythm discrimination, in children treated for a cerebellar medulloblastoma. Research in Developmental Disabilities, 2014, 35, 2053-2068.	2.2	14
126	Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children. Neuro-Oncology, 2020, 22, 1686-1695.	1.2	14

#	Article	IF	CITATIONS
127	Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. Journal of Neurosurgery: Pediatrics, 2005, 103, 312-318.	1.3	13
128	Intracerebral small round cell tumor: An unusual case with EWSâ€WT1 translocation. Pediatric Blood and Cancer, 2008, 51, 545-548.	1.5	13
129	Medulloblastoma: what is the role of molecular genetics?. Expert Review of Anticancer Therapy, 2008, 8, 1169-1181.	2.4	13
130	Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases. Child's Nervous System, 2013, 29, 565-571.	1.1	13
131	Current and evolving knowledge of prognostic factors for pediatric ependymomas. Future Oncology, 2013, 9, 183-191.	2.4	13
132	A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. Oncogene, 2019, 38, 6479-6490.	5.9	13
133	High Prevalence of Developmental Venous Anomaly in Diffuse Intrinsic Pontine Gliomas: A Pediatric Control Study. Neurosurgery, 2020, 86, 517-523.	1.1	13
134	Treatment-related Myelodysplastic Syndrome After Temozolomide Use in a Child. Journal of Pediatric Hematology/Oncology, 2008, 30, 857-859.	0.6	12
135	Time perception in children treated for a cerebellar medulloblastoma. Research in Developmental Disabilities, 2013, 34, 480-494.	2.2	12
136	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 2022, 304, 174-182.	7.3	12
137	Neuropathological and Neuroradiological Spectrum of Pediatric Malignant Gliomas: Correlation With Outcome. Neurosurgery, 2011, 69, 215-224.	1.1	11
138	Chordoma in children: Case-report and review of literature. Reports of Practical Oncology and Radiotherapy, 2016, 21, 1-7.	0.6	11
139	Histone H3 genotyping refines clinico-radiological diagnostic and prognostic criteria in DIPG. Acta Neuropathologica, 2016, 131, 795-796.	7.7	11
140	Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features. European Radiology, 2021, 31, 8913-8924.	4.5	11
141	Utility of Cerebrospinal Fluid Cytology in Newly Diagnosed Childhood Ependymoma. Journal of Pediatric Hematology/Oncology, 2010, 32, 515-518.	0.6	10
142	Primary Leptomeningeal Gliomatosis in Children and Adults. Neurosurgery, 2016, 78, 343-352.	1.1	10
143	Parental stress and paediatric acquired brain injury. Brain Injury, 2018, 32, 1780-1786.	1.2	10
144	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. Clinical Cancer Research, 2020, 26, 1856-1865.	7.0	10

#	Article	IF	CITATIONS
145	A CBF decrease in the left supplementary motor areas: New insight into postoperative pediatric cerebellar mutism syndrome using arterial spin labeling perfusion MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3339-3349.	4.3	10
146	Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma. Cancers, 2021, 13, 53.	3.7	10
147	Pediatric ependymomas. Current Opinion in Oncology, 2011, 23, 638-642.	2.4	9
148	A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. Journal of Neuro-Oncology, 2013, 113, 127-134.	2.9	9
149	Impact of extensive surgery in multidisciplinary approach of pterygopalatine/infratemporal fossa soft tissue sarcoma. Pediatric Blood and Cancer, 2013, 60, 928-934.	1.5	9
150	Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neuro-Oncology Practice, 2017, 4, 161-170.	1.6	9
151	Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma. Journal of Neurosurgery: Pediatrics, 2018, 22, 678-683.	1.3	9
152	Anatomo-functional study of the cerebellum in working memory in children treated for medulloblastoma. Journal of Neuroradiology, 2019, 46, 207-213.	1.1	9
153	CT and Multimodal MR Imaging Features of Embryonal Tumors with Multilayered Rosettes in Children. American Journal of Neuroradiology, 2019, 40, 732-736.	2.4	9
154	Object Detection Improves Tumour Segmentation in MR Images of Rare Brain Tumours. Cancers, 2021, 13, 6113.	3.7	9
155	Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI. American Journal of Neuroradiology, 2020, 41, 1733-1739.	2.4	8
156	Visual Agnosia After Treatment of a Posterior Fossa Ependymoma in a 16-Month-Old Girl. Journal of Child Neurology, 2001, 16, 698-704.	1.4	7
157	Maternal stress and pediatric brain cancer: A French study. Journal of Psychosocial Oncology, 2019, 37, 96-109.	1.2	7
158	Appraisal of the current staging system for residual medulloblastoma by volumetric analysis. Child's Nervous System, 2011, 27, 2101-2106.	1.1	6
159	Epileptic seizures in anaplastic gangliogliomas. British Journal of Neurosurgery, 2017, 31, 227-233.	0.8	6
160	High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2156-e2166.	3.6	6
161	Pneumomediastinum: A rare, impressive but benign complication of chemotherapy-induced emesis in children., 1998, 31, 182-184.		5
162	Oncolytic Virotherapy of Meningiomas in Vitro with Replication-competent Adenovirus. Neurosurgery, 2005, 56, 146-154.	1.1	5

#	Article	IF	CITATIONS
163	Do medulloblastoma tumors meet the food and drug administration criteria for anti-erbB2 therapy with trastuzumab?. Pediatric Blood and Cancer, 2008, 50, 163-166.	1.5	5
164	Forniceal glioma in children. Journal of Neurosurgery: Pediatrics, 2009, 4, 249-253.	1.3	5
165	Integrated analysis of longâ€term growth and bone development in pediatric and adolescent patients receiving bevacizumab. Pediatric Blood and Cancer, 2019, 66, e27487.	1.5	5
166	Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab097.	0.7	5
167	Deciphering the genetic and epigenetic landscape of pediatric bithalamic tumors. Brain Pathology, 2022, 32, e13039.	4.1	5
168	Stability of medulloblastoma subgroups at tumour recurrence. Nature Reviews Neurology, 2014, 10, 5-6.	10.1	4
169	Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. Drugs in R and D, 2014, 14, 13-23.	2.2	4
170	Reprint of "Chordoma in children: Case-report and review of literature― Reports of Practical Oncology and Radiotherapy, 2016, 21, 412-417.	0.6	4
171	Cognitive Profile of Children With Intracranial Germ Cell Tumor According to Tumor Location. Journal of Pediatric Hematology/Oncology, 2018, 40, e424-e428.	0.6	4
172	Patients with High-Grade Gliomas and Caf \tilde{A} ©-au-Lait Macules: Is Neurofibromatosis Type 1 the Only Diagnosis?. American Journal of Neuroradiology, 2019, 40, E30-E31.	2.4	4
173	Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. American Journal of Neuroradiology, 2019, 40, 568-575.	2.4	4
174	Stratégies de prise en charge nutritionnelle spécifiquesÂ: l'enfant en cancérologie. Nutrition Clinique Et Metabolisme, 2005, 19, 234-237.	0.5	3
175	Atypical teratoid rhabdoid tumor mimicking beta-catenin-positive nodular medulloblastoma. Acta Neuropathologica, 2011, 121, 429-430.	7.7	3
176	Conceptions of time in children treated for malignant cerebellar tumours. Brain Injury, 2014, 28, 1334-1341.	1.2	3
177	A novel case of cribriform neuroepithelial tumor: A potential diagnostic pitfall in the ventricular system. Pediatric Blood and Cancer, 2021, 68, e29037.	1.5	3
178	Adjuvant Chemotherapy for Ependymoma: Is It Necessary for All Children Under Five Years of Age?. Journal of Clinical Oncology, 2001, 19, 3588-3589.	1.6	2
179	DIPG-20. PRE-RANDOMISATION CENTRAL REVIEW AND REAL-TIME BIOMARKERS SCREENING IN THE MULTICENTRE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL: LESSONS LEARNT FROM THE FIRST 120 BIOPSIES. Neuro-Oncology, 2018, 20, i52-i53.	1.2	2
180	New stratification for early childhood medulloblastoma. Pediatric Medicine, 2018, 1, 10-10.	2.7	2

#	Article	lF	CITATIONS
181	Regarding "Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma― Neuro-Oncology Practice, 2020, 7, 572-573.	1.6	2
182	Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. Neuro-Oncology Advances, 2020, 2, vdaa075.	0.7	2
183	Pediatric brain tumors as a developmental disease. Current Opinion in Oncology, 2021, 33, 608-614.	2.4	2
184	Translating preclinical hopes into clinical reality for children with ependymoma. Neuro-Oncology, 2015, 17, 1545-1546.	1.2	1
185	The dark matter of diffuse intrinsic pontine gliomas: an update. Expert Opinion on Orphan Drugs, 2019, 7, 11-20.	0.8	1
186	CNS tumors with YWHAE:NUTM2 and KDM2B-fusions present molecular similarities to extra-CNS tumors having BCOR internal tandem duplication or alternative fusions. Acta Neuropathologica Communications, 2021, 9, 176.	5.2	1
187	HG-46RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMAS: CLINICAL, BIOLOGICAL, RADIOLOGICAL AND THERAPEUTIC FACTORS CORRELATING WITH THE SURVIVAL. Neuro-Oncology, 2016, 18, iii57.4-iii58.	1.2	0
188	HGG-41. Glioma oncogenesis in the constitutional mismatch repair deficiency (CMMRD) syndrome. Neuro-Oncology, 2022, 24, i70-i70.	1.2	0
189	EPEN-24. Biological markers of ependymoma in children and adolescents (BIOMECA): Systematic comparison of methods for the precise evaluation of biomarkers for ependymoma diagnosis and prognostication. Neuro-Oncology, 2022, 24, i44-i44.	1.2	O
190	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
191	HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma. Neuro-Oncology, 2022, 24, i69-i70.	1.2	О